Valomaciclovir stearate

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 558295

CAS#: 195156-77-5 (stearate)

Description: Valomaciclovir stearate (A-174606.0; ABT-606; EPB-348; MIV-606; RP-606) is a DNA polymerase inhibitor potentially for treatment of acute herpes zoster and EB virus infection. Valomaciclovir stearate is an orally available and a prodrug of Valomaciclovir with broad-spectrum antiviral activity against a variety of important herpesviruses, including Epstein-Barr virus, or EBV (the first virus to be directly associated with human cancer), varicella zoster virus, or herpes zoster (cause of shingles), and herpes simplex virus 1 and 2.

Chemical Structure

Valomaciclovir stearate
CAS# 195156-77-5 (stearate)

Theoretical Analysis

MedKoo Cat#: 558295
Name: Valomaciclovir stearate
CAS#: 195156-77-5 (stearate)
Chemical Formula: C33H58N6O5
Exact Mass: 618.4469
Molecular Weight: 618.864
Elemental Analysis: C, 64.05; H, 9.45; N, 13.58; O, 12.93

Price and Availability

Size Price Availability Quantity
1.0mg USD 150.0 Ready to Ship
5.0mg USD 550.0 Ready to Ship
10.0mg USD 950.0 Ready to Ship
25.0mg USD 1650.0 Ready to Ship
50.0mg USD 2950.0 Ready to Ship
Bulk inquiry

Related CAS #: 195156-77-5 (stearate)   195157-39-2 (HCl)   195156-78-6 (TFA)   195157-34-7    

Synonym: Valomaciclovir stearate; A-174606.0; A 174606.0; A174606.0; ABT-606; ABT 606; ABT606; EPB-348; EPB348; EPB 348; MIV-606; MIV 606; MIV606; RP-606; RP606; RP 606;

IUPAC/Chemical Name: (R)-4-((L-valyl)oxy)-2-((2-amino-6-oxo-1,6-dihydro-9H-purin-9-yl)methyl)butyl stearate


InChi Code: InChI=1S/C33H58N6O5/c1-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-27(40)44-23-26(20-21-43-32(42)28(34)25(2)3)22-39-24-36-29-30(39)37-33(35)38-31(29)41/h24-26,28H,4-23,34H2,1-3H3,(H3,35,37,38,41)/t26-,28+/m1/s1


Appearance: White to off-white solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

Biological target: Valomaciclovir stearate (A-174606.0; ABT-606; EPB-348; MIV-606; RP-606) is a DNA polymerase inhibitor.
In vitro activity: TBD
In vivo activity: TBD

Preparing Stock Solutions

The following data is based on the product molecular weight 618.864 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol: TBD
In vitro protocol: TBD
In vivo protocol: TBD

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.


Dilution Calculator

Calculate the dilution required to prepare a stock solution.

1: Andrei G, Snoeck R. Advances and Perspectives in the Management of Varicella- Zoster Virus Infections. Molecules. 2021 Feb 20;26(4):1132. doi: 10.3390/molecules26041132. PMID: 33672709; PMCID: PMC7924330.

2: Krecmerova M. Amino Acid Ester Prodrugs of Nucleoside and Nucleotide Antivirals. Mini Rev Med Chem. 2017;17(10):818-833. doi: 10.2174/1389557517666170216151601. PMID: 28215138.

3: El Hayderi L, Rübben A, Nikkels AF. Alpha-Herpesviridae in der Dermatologie : Herpes-simplex-Virus Typ I und II [The alpha-herpesviridae in dermatology : Herpes simplex virus types I and II. German version]. Hautarzt. 2017 Mar;68(3):181-186. German. doi: 10.1007/s00105-016-3929-5. PMID: 28197699.

4: El Hayderi L, Rübben A, Nikkels AF. The alpha-herpesviridae in dermatology : Herpes simplex virus types I and II. Hautarzt. 2017 Dec;68(Suppl 1):1-5. English. doi: 10.1007/s00105-016-3919-7. PMID: 28197698.

5: De Paor M, O'Brien K, Fahey T, Smith SM. Antiviral agents for infectious mononucleosis (glandular fever). Cochrane Database Syst Rev. 2016 Dec 8;12(12):CD011487. doi: 10.1002/14651858.CD011487.pub2. PMID: 27933614; PMCID: PMC6463965.

6: De SK, Hart JC, Breuer J. Herpes simplex virus and varicella zoster virus: recent advances in therapy. Curr Opin Infect Dis. 2015 Dec;28(6):589-95. doi: 10.1097/QCO.0000000000000211. PMID: 26524331.

7: Andrei G, Snoeck R. Advances in the treatment of varicella-zoster virus infections. Adv Pharmacol. 2013;67:107-68. doi: 10.1016/B978-0-12-405880-4.00004-4. PMID: 23886000.

8: Tyring SK, Plunkett S, Scribner AR, Broker RE, Herrod JN, Handke LT, Wise JM, Martin PA; Valomaciclovir Zoster Study Group. Valomaciclovir versus valacyclovir for the treatment of acute herpes zoster in immunocompetent adults: a randomized, double-blind, active-controlled trial. J Med Virol. 2012 Aug;84(8):1224-32. doi: 10.1002/jmv.23329. PMID: 22711350.

9: Price NB, Prichard MN. Progress in the development of new therapies for herpesvirus infections. Curr Opin Virol. 2011 Dec;1(6):548-54. doi: 10.1016/j.coviro.2011.10.015. PMID: 22162744; PMCID: PMC3230035.

10: Andrei G, Snoeck R. Emerging drugs for varicella-zoster virus infections. Expert Opin Emerg Drugs. 2011 Sep;16(3):507-35. doi: 10.1517/14728214.2011.591786. Epub 2011 Jun 24. PMID: 21699441.

Additional Information

CAS#195157-34-7 (Valomaciclovir)